Healthcare -
Biotechnology - NASDAQ - US
$ 0.698
0.722 %
$ 36.1 M
Market Cap
-1.07
P/E
1. INTRINSIC VALUE
Balance Sheet
Xilio Therapeutics, Inc.
| Current Assets | 60.2 M |
| Cash & Short-Term Investments | 55.3 M |
| Receivables | 0 |
| Other Current Assets | 4.94 M |
| Non-Current Assets | 10.8 M |
| Long-Term Investments | 0 |
| PP&E | 9.06 M |
| Other Non-Current Assets | 1.78 M |
| Current Liabilities | 27.3 M |
| Accounts Payable | 2.57 M |
| Short-Term Debt | 1.19 M |
| Other Current Liabilities | 23.5 M |
| Non-Current Liabilities | 26.2 M |
| Long-Term Debt | 6.95 M |
| Other Non-Current Liabilities | 19.3 M |
EFFICIENCY
Earnings Waterfall
Xilio Therapeutics, Inc.
| Revenue | 6.34 M |
| Cost Of Revenue | 0 |
| Gross Profit | 6.34 M |
| Operating Expenses | 66.9 M |
| Operating Income | -60.6 M |
| Other Expenses | -2.34 M |
| Net Income | -58.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Xilio Therapeutics, Inc.
| Net Income | -58.2 M |
| Depreciation & Amortization | 1.64 M |
| Capital Expenditures | -36 K |
| Stock-Based Compensation | 6.43 M |
| Change in Working Capital | 31.8 M |
| Others | 30.3 M |
| Free Cash Flow | -18.4 M |
Wall Street Analysts Price Targets
Xilio Therapeutics, Inc.
XLO has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
XLO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Xilio Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
8.61 K USD 2
9-12 MONTHS
0 USD 0
Bought
30.1 M USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.83 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non-qualified stock options to purchase 10,700 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
globenewswire.com
- 5 days ago
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors.
globenewswire.com
- 3 weeks ago
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutive capital received, under certain circumstances Financing co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and other new and existing investors WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the closing of its previously announced underwritten public offering of pre-funded warrants and accompanying common stock warrants for initial gross proceeds of approximately $50.0 million before deducting underwriting discounts and commissions and offering expenses.
globenewswire.com
- 1 month ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective June 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
globenewswire.com
- 1 month ago
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten public offering of pre-funded warrants to purchase 66,676,000 shares of common stock (the “pre-funded warrants”), accompanied by Series A warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series A warrants”), Series B warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series B warrants”) and Series C warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series C warrants”). The combined public offering price of one pre-funded warrant, one Series A warrant, one Series B warrant and one Series C warrant, which are being sold together but are immediately separable, is $0.7499, which is equal to the combined offering price of the pre-funded warrants, Series A warrants, Series B warrants and Series C warrants, less the $0.0001 per share exercise price of the pre-funded warrants. The offering is expected to close on or about June 5, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Xilio.
globenewswire.com
- 1 month ago
Xilio Therapeutics Announces Proposed Public Offering
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants), Series B warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants) and Series C warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants). All of the securities to be sold in the proposed offering will be offered by Xilio. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
globenewswire.com
- 1 month ago
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases
globenewswire.com
- 1 month ago
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell engager programs utilizing Xilio's novel ATACR and SEECR formats, with first development candidates anticipated in second half of 2025 WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2025.
globenewswire.com
- 2 months ago
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
globenewswire.com
- 2 months ago
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present updated data from its ongoing Phase 2 clinical trial investigating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
globenewswire.com
- 2 months ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 22,900 shares of its common stock to three new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
globenewswire.com
- 3 months ago
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.64 per share a year ago.
zacks.com
- 3 months ago
8. Profile
Summary
Xilio Therapeutics, Inc. XLO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 36.1 M
Dividend Yield
0.00%
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Contact
828 Winter Street, Waltham, MA, 02451
https://www.xiliotx.com
IPO
Date
Oct. 22, 2021
Employees
64
Officers
Mr. Christopher Frankenfield
Chief Financial Officer & Chief Operating Officer
Dr. Katarina Luptakova M.D.
Chief Medical Officer
Mr. Kevin M. Brennan
Senior Vice President of Finance & Accounting
Dr. Scott Coleman Ph.D.
Chief Development Officer
Dr. Rene Russo BCPS, Pharm.D.
President, Chief Executive Officer & Director
Dr. Uli Bialucha Ph.D.
Chief Scientific Officer
Ms. Caroline Hensley
Chief Legal Officer